Impact of baseline characteristics on clinical remission achievement in severe asthma

Abstract

<b>Introduction:</b> Clinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. <b>Aims:</b> This post hoc analysis of REDES data examines the impact of baseline characteristics on clinical remission achievement. <b>Methods:</b> REDES, a real-world, retrospective observational study, enrolled adults with severe eosinophilic asthma across Spain who were newly prescribed mepolizumab with ≥12 months of medical records pre-enrollment. Clinical remission was defined as a composite measure (OCS-free at 52 weeks, exacerbation-free for 52 weeks and ACT score ≥20 at Week 52). Baseline characteristics were assessed in those who did/did not achieve clinical remission. <b>Results:</b> Overall, 96/260 (37%) patients met the clinical remission definition; baseline demographics were similar between the 2 groups (<b>Table</b>). At baseline, patients achieving clinical remission at Week 52 had higher BEC, better lung function, lower maintenance OCS requirements and were more likely to be non-atopic and have nasal polyps versus those who did not (<b>Table</b>). <b>Conclusions:</b> Our results show that clinical remission in severe asthma is achievable with mepolizumab and highlight the baseline clinical characteristics that are more commonly associated with this outcome. Further exploration is required to determine whether earlier initiation of mepolizumab may enable a greater ability to achieve clinical remission. <b>Funding:</b> GSK (213172)